From dashboards to strategic decisions: explainable AI is the new brain in pharma

An Analysis piece finds explainable AI is the new brain behind pharma's decision-making process for PR and insights leaders.

Introduction

The intersection of reputation risk, market volatility, and scientific breakthroughs has ushered in a period of unprecedented pressure for the pharma and biotech companies. Business leaders at these companies are being pushed to make high stake decisions quickly and with complete confidence. This pressure trickles down to the PR and insights leaders who keep the executives in the knowhow of the latest to drive their decisions across different functions.

While there is no dearth of data, the abundance has only complicated the task of PR and insights leaders. The fragmented nature of dashboards, siloed datasets, and lack of prescriptive analytics has just added to their challenges. What we are witnessing for years now is something called the dashboard dilemma!

The Dashboard Dilemma

This is a situation wherein the data fails to deliver clarity and direction to drive decisions! The dependency of conventional dashboards that often fail to connect data to the context. They lack the analytical depth that can bring about strategic clarity.

Agreed, AI has changed a great deal of this. But the AI-powered analytics tools today often operate as what is popularly called “black boxes”. These tools lack transparency into the analysis methodology to understand how the conclusions were arrived at. For highly regulated industries like pharma, this can create compliance risks – something that no one would want!

“For pharma, the greatest challenge with AI isn’t adoption—it’s trust. Without explainability, black-box models create risk of compliance and patient confidence – the two non-negotiables of the industry. The need of the hour is to move beyond opaque models for clarity of insights”, says Rajesh Kari, Global Business Leader and Vice President, InfoVision Inc.

In an industry where reputations can pivot overnight—due to a clinical trial result, policy change, or viral misinformation—pharma leaders can no longer rely on static dashboards or backward-looking media trackers. The future belongs to those who move faster, with clarity and confidence.

ExplainableAI (XAI): Making Intelligence Transparent

Explainable AI (XAI) is a system that couples their analytical outputs with human-understandable justifications. They use NLP or predictive model to perform complex analytics tasks. But then they also allow users to track back the logic and the methodology that brought them to the decisions.

So what does this mean for pharma? This means XAI models can go beyond the ‘what’ behind a situation and provide answers to why, how, and what to do next.

Let’s put this in a real-life parlance. In case of reputational risk, XAI reveals why public sentiment is shifting dramatically and what can be done to mitigate it. Similarly XAI can transform insights teams from data gatekeepers to trusted advisors for defining the next strategic move. It can analyze trends, evaluate their propensity to drive a dramatic shift, and recommend strategies to leverage them – and do all while providing a rationale behind it.

Explainable AI powered platforms like AlphaMetricx are emerging as the go-to platform for pharma’s PR and insights leaders – to move beyond merely monitoring the public discourse and understanding them at contextual level, and acting on them.

Strategic urgency for XAI in pharma

The pharma regulatory environments are tightening up, stakeholder expectations are growing, and crisis cycles are shortening. This means pharma leaders need more than just analytical dashboards. They need a layer of strategic intelligence that can hold up against internal and external scrutiny.

Integrating XAI in the analytical processes can help pharma companies break the siloes and have a more cross-functional approach to data analytics. They can have a more coordinated understanding of insights and their relevance for PR teams, medical affairs teams, commercial teams, etc.

Mr Kari said: "When we collaborate with our pharma partners we help them make a shift in how they embrace AI. We integrate it into their qualitative and quantitative research processes to help them move beyond static reports. Whether it is an ATU study, a brand awareness study, or patient journey study, we employ XAI to decode shifts in perceptions, emerging concerns, impact on treatment decisions, etc. Our XAI implementation explains not only the results but also the drivers.

"For example, one of our global pharma brand used AlphaMetricx to detect narratives around pricing concerns – especially when they were preparing to launch a new drug. Our platform identified a recent policy debate as the trigger for this concern. Furthermore, when we applied our Brand Momentum Index tracking to this data, we could forecast a potential spike in media conversations. Using these insights, the communications team activated a tailored messaging that shifting their brand sentiment.

"Similarly, our AI powered platform AlphaMetricx transforms media monitoring by identifying narratives that are gaining traction, mapping influencer ecosystems, decoding issues that resonate across audience groups, identifying emerging reputation risks, etc."

Explainable AI for Pharma Leaders: The Intelligence Core Needed Now

AI for pharma industry is no longer just a good-to-have but a must-have. The bigger question is how to integrate XAI in research and analytics and make it your strategic muscle. AI is here to stay and each industry needs to figure out a way to embrace it. In fact, pharma companies need to stop treating AI as just a toolkit and view it as a partner algorithm with human like cognitive capabilities.

As pharma companies recalibrate their operations, PR and insights teams are no longer in support roles. They are strategic engines tasked with the responsibility of driving decisions. Integrating XAI accelerates this transition. It gives them the ability to question, validate, and defend insights presented to executive teams as well as regulators and third party stakeholders. This becomes crucial during a phase when pharma decisions are to be made with speed, rigor and accountability.

The future of pharma leadership will belong to those who leverage AI in best possible way to contextualize data and set the direction for the organizational teams. The future will be dominated not by dashboards but by strategic clarity.